Golimumab - Next gen biotech blockbusters

Drug: Golimumab
Company: Johnson & Johnson's Centocor, Schering-Plough

Scoop: Golimumab is a human monoclonal antibody for the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. It is being studied as an every four week subcutaneous injection as well as an intravenous infusion therapy. If approved, golimumab would join the ranks of such anti-TNF blockbusters as Enbrel, Humira and J&J's own Remicade. Golimumab's advantage? The drug requires injections only once a month, compared to higher frequencies for other existing drugs. The companies submitted an NDA for the drug in both the U.S. and Europe last month. 

Golimumab - Next gen biotech blockbusters

Suggested Articles

What a difference a day makes in biotech.

A report out this week by PwC thinks that biotech could be in for a good year for deals as it sees the momentum from 2019 growing.

A drug developed at Temple restores a mechanism in brain cells that prevents the toxic buildup of the proteins amyloid beta and tau in Alzheimer's.